Scholarlink

<p>Marine actinobacteria continues to represent an important route to the discovery of novel metabolites for the development of therapeutics in health care sectors. Most of the secondary metabolites produced from marine <i>Streptomyces</i> sp. exhibited broad-spectrum activity against many diseases. The study’s main aim was to evaluate the bioactive potential of actinomycetes isolated from marine soil samples obtained from the Southeast coast of Tamil Nadu, India. The potent marine actinomycete VITND1 was identified as <i>Streptomyces</i> sp. based on morphological and biochemical characterization. The <i>Streptomyces</i> sp. VITND1 strain was screened using the cross-streak assay method against five bacterial pathogens. GC-MS analysis was done to identify the bioactive compounds. Further, the identified bioactive compounds were analyzed by molecular docking. The crude extract of VITND1 exhibited susceptibility against <i>Pseudomonas aeruginosa</i> with a 19.6 ± 0.16 mm zone of inhibition at 1000 µg/mL. The extract exhibited a significant 72% antioxidant activity, 56% anti-inflammatory activity and 91% anti-diabetic activity. GC-MS analysis of VIT ND1 crude extract confirmed the presence of 49 different bioactive compounds. Among these, 15 compounds were identified as active and further subjected to molecular docking analysis. The study confirmed the potential bioactive compounds (Pub Chem CID: 4916205, 542106, and 101687) for further therapeutic use. The extracts from <i>Streptomyces</i> sp. VITND1 have various bioactivities, including anti-bacterial, anti-oxidant, anti-inflammatory and anti-diabetic properties. The bioactive compounds Molecule 1 (4916205); Molecule 10 (542106) and Molecule 6 (101687) showed promising binding affinity towards receptor protein targets in the molecular docking studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In silico, molecular docking and in vitro bioactivity of compounds extracted from marine Streptomyces sp. VITND1

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月15日

查看全文
  • Nirmaladevi Ponnusamy,
  • V. Mohanasrinivasan.,
  • A. Mohanapriya.,
  • S. Jemimah Naine.,
  • M. Hemalatha,
  • Kothari Neeti Suresh,
  • Sanjeev K. Ganesh,
  • C. Subathra Devi.

摘要

Marine actinobacteria continues to represent an important route to the discovery of novel metabolites for the development of therapeutics in health care sectors. Most of the secondary metabolites produced from marine Streptomyces sp. exhibited broad-spectrum activity against many diseases. The study’s main aim was to evaluate the bioactive potential of actinomycetes isolated from marine soil samples obtained from the Southeast coast of Tamil Nadu, India. The potent marine actinomycete VITND1 was identified as Streptomyces sp. based on morphological and biochemical characterization. The Streptomyces sp. VITND1 strain was screened using the cross-streak assay method against five bacterial pathogens. GC-MS analysis was done to identify the bioactive compounds. Further, the identified bioactive compounds were analyzed by molecular docking. The crude extract of VITND1 exhibited susceptibility against Pseudomonas aeruginosa with a 19.6 ± 0.16 mm zone of inhibition at 1000 µg/mL. The extract exhibited a significant 72% antioxidant activity, 56% anti-inflammatory activity and 91% anti-diabetic activity. GC-MS analysis of VIT ND1 crude extract confirmed the presence of 49 different bioactive compounds. Among these, 15 compounds were identified as active and further subjected to molecular docking analysis. The study confirmed the potential bioactive compounds (Pub Chem CID: 4916205, 542106, and 101687) for further therapeutic use. The extracts from Streptomyces sp. VITND1 have various bioactivities, including anti-bacterial, anti-oxidant, anti-inflammatory and anti-diabetic properties. The bioactive compounds Molecule 1 (4916205); Molecule 10 (542106) and Molecule 6 (101687) showed promising binding affinity towards receptor protein targets in the molecular docking studies.